Changes in biomarkers in patients with idiopathic pulmonary fibrosis (IPF) treated with nintedanib and sildenafil

Conclusions: In the INSTAGE trial, biomarkers relevant to the pathophysiology of IPF were reduced in subjects treated with nintedanib plus sildenafil vs nintedanib alone for 24 weeks. These results support the potential benefits of this combination suggested by clinical endpoints.

Source: European Respiratory Journal - November 20, 2019 Category: Respiratory Medicine Authors: White, E., Crestani, B., Günther, A., Maher, T. M., Ittrich, C., Diefenbach, C., Rohr, K. B., Quaresma, M., Kolb, M. Tags: Idiopathic interstitial pneumonias Source Type: research